NASD · Healthcare · Biotechnology · Israel
Silexion Therapeutics Corp is a micro cap company (market value under $300 million) in the Biotechnology industry.
Silexion Therapeutics is a clinical-stage biotechnology company developing treatments for cancers caused by KRAS gene mutations. The company uses small interfering RNA technology to silence the mutated KRAS oncogene, preventing production of cancer-driving proteins. Its lead candidate, SIL204, targets locally advanced pancreatic cancer patients with KRAS mutations and is administered directly into tumors combined with standard chemotherapy.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Silexion Therapeutics Corp stock.
Not valued: We cannot value this company yet.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on SLXN yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.